Evidence map›Paper›PMID 41297556›Full record

ArticleThe Journal of infectious diseases2026

New Viability Assays for Acanthamoeba castellanii Trophozoites and Cysts Allow Rapid Assessment of Drug Activity.

Carrie A Flynn, Rebecca I Colón-Ríos, Andrew Harmez, William F Flynn, Barbara I Kazmierczak

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carrie A FlynnDepartment of Microbial Pathogenesis, Yale School of Medicine, New Haven.ORCID 0000-0002-9663-5566
Rebecca I Colón-RíosDepartment of Microbial Pathogenesis, Yale School of Medicine, New Haven.ORCID 0000-0001-7634-676X
Andrew HarmezDepartment of Medicine, Yale School of Medicine, New Haven.ORCID 0009-0001-1640-075X
William F FlynnThe Jackson Laboratory for Genomic Medicine, Farmington.ORCID 0000-0001-6533-0340
Barbara I KazmierczakDepartments of Medicine and Microbial Pathogenesis, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-8162-803X

Funding

Determining the mechanism of cell death of small molecules produced by Pseudomonas aeruginosa against Acanthamoeba castellaniiF31AI181569 · NIAID · YALE UNIVERSITY · PI COLÓN RÍOS, REBECCA ISABEL · 2024 to 2025
$83k
National Institute of Allergy and Infectious DiseasesNIAID NIH HHS F31 AI181569NIH HHS AI149628
6 · The paper itself

Abstract

Pathogenic free-living amoebae such as Acanthamoeba castellanii are present in soil and water worldwide. A. castellanii causes systemic infections with very high mortality rates, yet drugs specifically targeting this pathogen are not available. Methods to reliably generate and assay cysts, which drive infection recurrence and drug resistance, are unavailable in a high-throughput format suitable for drug screening and testing. In this study, we developed a robust and reproducible protocol for encysting A. castellanii as well as a high-throughput, quantitative cyst viability assay using fluorescent live/dead staining coupled with microscopy and automated image analysis. These methods, coupled with optimized techniques for measuring trophozoite viability and pseudocyst formation, were used to screen the activity of 16 clinically relevant drugs and disinfectants. Four agents, including caspofungin, were active against both trophozoites and cysts.

Indexed as

Acanthamoeba castellaniiTrophozoitesDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysParasitic Sensitivity TestsAcanthamoebaencystmentfree-living amoebaeviability assay

Identifiers

PMID41297556
PMCPMC13017141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.